Spyglass Capital Management LLC Ascendis Pharma A/S Transaction History

Spyglass Capital Management LLC

$1.48 Billion
Q3 2024

A detailed history of Spyglass Capital Management LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Spyglass Capital Management LLC holds 652,841 shares of ASND stock, worth $89 Million. This represents 6.57% of its overall portfolio holdings.

Number of Shares

652,841

Previous 662,888 1.52%

Holding current value

$89 Million

Previous $90.4 Million 7.84%

% of portfolio

6.57%

Previous 6.62%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $1.14 Million - $1.54 Million	-10,047 Reduced 1.52%	652,841 $97.5 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $5.91 Million - $7.5 Million	48,781 Added 7.94%	662,888 $90.4 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $9.15 Million - $11.8 Million	74,159 Added 13.73%	614,107 $92.8 Million
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $6.43 Million - $9.51 Million	-74,670 Reduced 12.15%	539,948 $68 Million
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $3.74 Million - $4.5 Million	-43,235 Reduced 6.57%	614,618 $57.6 Million
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $3.93 Million - $5.49 Million	-56,113 Reduced 7.86%	657,853 $58.7 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $51,925 - $62,756	-495 Reduced 0.07%	713,966 $76.6 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $23.4 Million - $31.1 Million	-235,454 Reduced 24.79%	714,461 $87.3 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $13.4 Million - $17.6 Million	-159,755 Reduced 14.4%	949,915 $98.1 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $7.36 Million - $11.1 Million	-94,320 Reduced 7.83%	1,109,670 $103 Million
Q1 2022 May 16, 2022	SELL	$102.18 - $135.75 $11 Million - $14.7 Million	-107,925 Reduced 8.23%	1,203,990 $141 Million
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $8.51 Million - $11.4 Million	-66,972 Reduced 4.86%	1,311,915 $176 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $28.9 Million - $45.3 Million	256,216 Added 22.82%	1,378,887 $220 Million
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $18.4 Million - $22 Million	151,566 Added 15.61%	1,122,671 $148 Million
Q1 2021 May 17, 2021	BUY	$124.92 - $173.33 $33.7 Million - $46.7 Million	269,511 Added 38.41%	971,105 $125 Million
Q4 2020 Feb 16, 2021	BUY	$151.2 - $182.76 $23.4 Million - $28.2 Million	154,572 Added 28.26%	701,594 $117 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $12.7 Million - $14.6 Million	94,918 Added 20.99%	547,022 $84.4 Million
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $11.2 Million - $15.7 Million	100,716 Added 28.66%	452,104 $66.9 Million
Q1 2020 May 15, 2020	BUY	$97.01 - $145.11 $9.74 Million - $14.6 Million	100,416 Added 40.01%	351,388 $39.6 Million
Q4 2019 Feb 14, 2020	BUY	$91.45 - $139.12 $10.7 Million - $16.3 Million	117,283 Added 87.73%	250,972 $34.9 Million
Q3 2019 Nov 14, 2019	BUY	$95.8 - $118.9 $2.2 Million - $2.73 Million	22,949 Added 20.72%	133,689 $12.9 Million
Q2 2019 Aug 14, 2019	BUY	$107.11 - $132.09 $2.21 Million - $2.73 Million	20,675 Added 22.96%	110,740 $12.8 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $2.92 Million - $6.11 Million	47,000 Added 109.14%	90,065 $10.6 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $2.38 Million - $3 Million	43,065 New	43,065 $2.7 Million

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Spyglass Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Spyglass Capital Management LLC with notifications on news.

Account

Spyglass Capital Management LLC Ascendis Pharma A/S Transaction History